Prenetics Global LtdPREEarnings & Financial Report
Nasdaq · Health Care · Laboratory Analytical Instruments
Prenetics (NASDAQ:PRE) is a health sciences company headquartered in Hong Kong, with a presence in the United States. It focuses on early detection, prevention, and treatment of diseases, particularly cancer.
Revenue
$74.7M
Gross Profit
$25.7M
Operating Profit
$-5.3M
Net Profit
N/A
Gross Margin
34.5%
Operating Margin
-7.2%
Net Margin
N/A
YoY Growth
N/A
Prenetics Global Ltd Q3 FY2022 Financial Summary
Prenetics Global Ltd reported revenue of $74.7M for Q3 FY2022, with a net profit of N/A (N/A margin). Cost of goods sold was $48.9M, operating expenses totaled $31.1M.
Key Financial Metrics
| Total Revenue | $74.7M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 34.5% |
| Operating Margin | -7.2% |
| Report Period | Q3 FY2022 |
Prenetics Global Ltd Quarterly Revenue & Net Profit History
Prenetics Global Ltd results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2023 | $92.0M | — | N/A | N/A |
| Q3 FY2022 | $74.7M | — | N/A | N/A |
| Q1 FY2022 | $57.5M | — | N/A | N/A |
Income Statement
| Q1 2022 | Q3 2022 | Q1 2023 | |
|---|---|---|---|
| Revenue | $57.5M | $74.7M | $92.0M |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q3 2022 | Q1 2023 | |
|---|---|---|---|
| Assets | N/A | N/A | N/A |
| Liabilities | N/A | N/A | N/A |
| Equity | N/A | N/A | N/A |
Cash Flow
No data available for this period